Please assess the completion status of the following clinical trial:

Trial Title: Zoledronic Acid and Positron Emission Tomography in Treating Patients With Advanced Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed non-small cell lung cancer~  * Stage IIIB (with pleural effusion) or stage IV disease~* Candidate for systemic therapy~* Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques or ≥ 10 mm by spiral CT scan~* No active brain metastases~  * More than 7 days since prior radiotherapy for brain metastases~ * Must be neurologically stable with no seizures within the past 3 weeks~PATIENT CHARACTERISTICS:~* ECOG performance status (PS) 0-2 OR Karnofsky PS 60-100%~* WBC ≥ 3,000/mm³~* ANC ≥ 1,500/mm³~* Platelet count ≥ 100,000/mm³~* Bilirubin ≤ 1.5 times upper limit of normal (ULN)~* AST or ALT ≤ 2.5 times ULN (5 times ULN if liver metastases present)~* Creatinine normal OR creatinine clearance ≥ 60 mL/min by Cockcroft-Gault formula~* No current active dental problems, including infection of the teeth or jawbone (maxilla or mandible)~* No dental or fixture trauma, or a current or prior diagnosis of osteonecrosis of the jaw, of exposed bone in the mouth, or of slow healing after dental procedures~* Not pregnant~* No uncontrolled intercurrent illness including, but not limited to, any of the following:~  * Ongoing or active infection~ * Symptomatic congestive heart failure~ * Unstable angina pectoris~ * Cardiac arrhythmia~ * Psychiatric illness/social situations that would limit compliance with study requirements~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* No prior or other concurrent bisphosphonates~* More than 2 weeks since prior surgery~* More than 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C) and recovered~* More than 7 days since prior palliative radiotherapy and recovered~* More than 6 weeks since prior and no planned dental or jaw surgery~* More than 30 days since prior participation in an investigational trial~* No other concurrent investigational agent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 3'-deoxy-3'-[18F]FLT PET & zoledronic acid (Type: EXPERIMENTAL): Patient should receive the dose of zoledronic acid within 48 hours of the first FLT PET scan. The second FLT PET scan will be done 6-8 days after the dose of zoledronic acid~Single photon emission computed tomography. Patient should receive the dose of zoledronic acid within 48 hrs of the first '3'-deoxy-3'-\[18F\]FLT PET scan. The second FLT PET scan will be done 6-8 days after the dose of zoledronic acid.

Based on this trial design, predict the completion outcome and termination type (if applicable).